Search Results - human+leukocyte+antigen

3 Results Sort By:
Cell Lines that Constitutively Express High-Frequency KRAS and P53 Mutations and Human Leukocyte Antigens (HLAs)
Abstract: Adoptive cell therapy (ACT) is a breakthrough form of cancer immunotherapy that utilizes tumor infiltrating lymphocytes (TILs) or genetically engineered T cells to attack tumor cells through recognition of tumor-specific antigens. A major hurdle in the development of ACT is the identification and isolation of T cells that recognize antigens...
Published: 5/8/2024   |   Inventor(s):  
Keywords(s): act, adoptive cell therapy, Antigen Presenting Cells, APC, cell lines, HLA, Human Leukocyte Antigen, Immunotherapy, KRAS, Levin, p53, Rosenberg, T Cell Receptor, TCR, TIL, Tumor Infiltrating Lymphocytes, Tumor-Specific Antigen
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Research Materials, TherapeuticArea > Infectious Disease
Method for HLA LOH Detection in Liquid Biopsies
Abstract: Human leukocyte antigen (HLA) LOH (LOH) is a known resistance mechanism by which cancers evade T cell receptor-(TCR-)based immunotherapies. This class of therapies includes immune checkpoint inhibition (ICI, e.g., Pembrolizumab), engineered TCR (T cell receptor)-T cell adoptive transfer, tumor infiltrating lymphocytes (TIL), T-cell engagers,...
Published: 5/8/2024   |   Inventor(s): Andrew Sinkoe, James Gulley, Cem Sievers
Keywords(s): Companion Diagnostic, Gulley, HLA, Human Leukocyte Antigen, ICI, Immune Checkpoint Inhibition, Immunotherapy, LOH, Loss of Heterozygosity, Sinkoe, T cell therapy
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Diagnostics
HLA-A*01:01 Restricted Human T Cell Receptor Recognizing the NRAS Q61K Hotspot Mutation
Abstract: Mutation of amino acid 61of the neuroblastoma rat sarcoma viral oncogene homologue (NRAS) is a known driver of oncogenesis in melanoma. Glutamine (Q) to lysine (K) mutation at this position of NRAS is prevalent in approximately 10% of all melanoma cases and associated with aggressive tumors and low patient survival. Therefore, Q61K mutated...
Published: 4/8/2024   |   Inventor(s): Paul Robbins, Steven Rosenberg, Gabriel Ivey, Almin Latani
Keywords(s): act, Adoptive Cell Transfer, HLA, Human Leukocyte Antigen, immuno-oncology, Immunotherapy, Neuroblastoma Rat Sarcoma Viral Oncogene, NRAS, Robbins, Rosenberg, T-Cell Receptor, TCR
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics, Collaboration Sought > Licensing